课题基金 / 基金详情

INNATE IMMUNITY, C-REACTIVE PROTEIN AND WOUND HEALING

INNATE IMMUNITY, C-REACTIVE PROTEIN AND WOUND HEALING
先天免疫、C 反应蛋白和伤口愈合
批准号:
6073567
负责人:
Lawrence Albert Potempa
金额:
$10.7万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-06-15 至 2000-12-14

项目摘要

项目成果

Lawrence Albert Potempa的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The acute phase host defense response (APR) is a survival mechanism of innate (non-specific, natural) immunity, triggered by the body as an immediate response to any minor or major threat to tissue integrity. Any damage or breach of tissues, such as occurs in wounds, compromises two important functions of innate immunity, 1.) as a barrier to the entry and movement of substances, and 2.) as a matrix within which reactions of host defenses and tissue repair are signaled and coordinated. A key protein of the APR is C-reactive protein (GRP). Recently, a conformational analog of CRP (i.e. mCRP) has been studied as a self- polymerizing protein naturally found in healthy, fibrous connective tissues. Intravenous mCRP has therapeutic activity in various animal models of cancer and infectious disease. This study will examine the rate and extent of tissue regeneration and repair of both partial thickness and full thickness wounds topically treated with recombinant mCRP (rmCRP), in both normal and impaired wound healing models. The goal of this work is to establish the safety and effectiveness of introducing a protein of innate immunity and the APR into injured tissues, and to establish the commercial potential of rmCRP for wound healing indications. PROPOSED COMMERCIAL APPLICATIONS: The discovery of mCRP as a naturally-occurring analog of CRP may one day be considered a key bridge to exploiting the natural (innate) immune system to therapeutic advantage. By depositing in tissues, mCRP may be used as a primary therapy to increase barriers (against infections, metastases, and inflammation), and as an adjunctive therapy to amplify beneficial reactions of the acute phase response. Essentially all patients with weakened tissues could be targeted for treatment. Because mCRP is a component of the "primitive" host defense system, it may be particularly effective in immunosuppressed individuals with impaired healing mechanisms. A recombinant form of mCRP suitable for commercialization is already available in large quantities.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NEW BROAD SPECTRUM DRUGS FOR OPPORTUNISTIC INFECTIONS
  • 批准号:
    6169924
  • 项目类别:
  • 资助金额:
    $19.85万
  • 财政年份:
    1996
  • 负责人:
    Lawrence Albert Potempa
  • 依托单位:
海外基金